TrialCancer science2018

Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial.

Yasuyoshi Morita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.